Antimicrobial Resistance (AMR): Vaccines
Trends in R&D funding for vaccines to fight AMR

Since 2017...
just 7% of investments in AMR R&D have gone towards vaccines.

There has been...
3x less funding for R&D in AMR vaccines than in AMR therapeutics.

94% of investments go toward fighting bacterial infections.
R&D for vaccines against priority bacterial pathogens receives 87% of funding.*

Just 2% (17 million USD) of AMR vaccine R&D funding goes toward developing vaccines against fungal infections.

Nearly half (45%)* of vaccines-only projects target specific diseases. Of these projects, tuberculosis (TB)-related research receives 33% (214 million USD) of total investments.

90% of investments (634 million USD) target AMR vaccines for humans.
Funding for animal health (9%) and cross-sectoral projects (2%) accounts for just 11% of total investments.

73% of funding (522 million USD) for AMR vaccines R&D is from the US and EU.
Vaccines R&D funding is highly concentrated in a small number of countries, with the US providing 54%, followed by the EU (19%) and the UK (13%).

73%
GAPS, OPPORTUNITIES, & RECOMMENDATIONS
- Increase support for R&D targeting priority pathogens of all types, including antifungals.
- Increase support for development of diagnostics across the full One Health spectrum.
- Align R&D of therapeutics, diagnostics, and vaccines targeting the same pathogens and/or diseases.
- Establish targets for AMR R&D based on priority needs.
- Focus on developing funding partnerships to create diversity in funding streams.

Source: Global AMR R&D Hub Dynamic Dashboard
Data from the Dynamic Dashboard covers AMR R&D funding from public and philanthropic donors globally since 1 January 2017.

dashboard.globalamrhub.org @GlobalAMRHub